GSK's blood cancer drug gets EU approval for multiple myeloma
1. GSK's Blenrep receives EU approval for relapsed/refractory multiple myeloma treatment.
FAQ
Why Bullish?
EU approval could enhance GSK's revenue and market position, similar to previous drug launches that positively impacted stock performance.
How important is it?
New drug approvals significantly influence investor perception and future revenue projections for GSK.
Why Short Term?
The approval will likely lead to immediate uptick in sales forecasts and investor sentiment.